Rahul Banerjee, MD, FACP (@RahulBanerjeeMD) ranks #3 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 81 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: MajesTEC-3, MonumenTAL-3, EXCALIBER-RRMM. CMS Open Payments lists $32,116 in 2025 general payments.
At a Glance
- 37 posts naming a trial since ASH 2025
- 19 trials discussed by name
- Multiple Myeloma: US #3, Global #3 · 81 physicians engaged
- Leading physician voice: #1 of 9 physicians on MonumenTAL-3; #1 of 8 physicians on CEPHEUS
- Presented at EHA 2026, IMS 2026 in 2026
- CMS Open Payments lists $32,116 in 2025 general payments.
This Month
What Rahul Banerjee, MD, FACP has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Rahul Banerjee, MD, FACP
Physicians who reposted Rahul Banerjee, MD, FACP’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #3 | #3 | 88/100 | 81 | 176 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Rahul Banerjee, MD, FACP presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- EHA 2026 · Oral (abstract S198)MajesTEC-3 teclistamab-daratumumab analysis by cytogenetic and functional riskSource: Multiple Myeloma Hub ↗
- IMS 2026 · PosterComparison of adverse event management costs of CAR-T therapies in 4L+ RRMM (PA-110, first author)
What Colleagues Are Saying About Rahul Banerjee, MD, FACP
2026 posts by fellow physicians that mention @RahulBanerjeeMD, quoted word for word.
#mmsm #EHA26 MajesTEC-3 high risk post hoc analysis @RahulBanerjeeMD Tec-Dara worked well in patients with 2HRCA or more as well as functionally high risk Really good results in hard to treat patients https://t.co/A2zYezcsXA
Bispecific in 2L myeloma — New Combinations enters the race @PlasmaCellPete @mbeksac56 @RahulBanerjeeMD @paurotero @thanosdimop and amazing team of invetigators/sponsor. MonumenTAL-3, EHA Plenary (Voorhees et al). 1:1:1, n=864: Tal+Dara+Pom (Tal-DP) vs Tal+Dara (Tal-D) vs DPd. https://t.co/sJvKwc4lg0
Trials Rahul Banerjee, MD, FACP Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| MajesTEC-3 | 9 | #2 of 15 | Sep 24, 2026 |
| MonumenTAL-3 | 5 | #1 of 9 | Jun 13, 2026 |
| EXCALIBER-RRMM | 4 | #2 of 13 | Oct 8, 2026 |
| MajesTEC-9 | 3 | #10 of 16 | Jun 13, 2026 |
| CERVINO | 2 | #4 of 11 | Sep 25, 2026 |
| anito-cel | 2 | #1 of 7 | Sep 24, 2026 |
| SUCCESSOR-2 | 2 | #4 of 15 | Sep 4, 2026 |
| PERSEUS | 1 | #2 of 10 | Sep 25, 2026 |
| CARTITUDE-2 | 1 | — | Sep 25, 2026 |
| CARTITUDE-4 | 1 | #6 of 9 | Sep 25, 2026 |
| MajesTEC-5 | 1 | #1 of 6 | Sep 25, 2026 |
| CEPHEUS | 1 | #1 of 8 | Jun 13, 2026 |
| MASTER | 1 | — | Dec 8, 2025 |
| GMMG-HD7 | 1 | — | Dec 8, 2025 |
| RedirecTT-1 | 1 | #4 of 10 | Dec 7, 2025 |
| AURIGA | 1 | — | Dec 6, 2025 |
| TECLISITO | 1 | — | Dec 4, 2025 |
| MIDAS | 1 | #3 of 5 | Nov 8, 2025 |
| LINKER-MM4 | 1 | — | Nov 8, 2025 |
Rahul Banerjee, MD, FACP on MajesTEC-3
#IMS26 Worth highlighting since pts with MM often aged 70+. We don't need OS plateau if myeloma remains in remission & no excess long-term mortality versus general population. Excellent 'functional cure' MajesTEC-3 data for tec-dara - I hope time-limited BsAb can replicate! https://t.co/uXn3UHkYPd
#IMS26 Elegant (post hoc) MajesTEC-3 analysis by @End_myeloma Unlike other myeloma drugs, I bet real-world tec-dara OS will look *better* than MajesTEC-3 did. Why? Because we now know PPx toci, PPx IVIG, etc - early BsAb deaths can be prevented, vs fatal PD with Dara-Pd can't. https://t.co/PjU0eGrzSQ
MagnetisMM-5 press release - elra outperformed DPd in myeloma with 1+ prior line! Obviously all eyes will be on this vs MajesTEC-3 (and more pertinently, MajesTEC-9)… … but this confirms that the heyday of Dara-Pd and Isa-Pd at first relapse is rapidly coming to an end 👏 https://t.co/alzQ0578XK
Rahul Banerjee, MD, FACP on MonumenTAL-3
#EHA2026 a new standard of care about to emerge in myeloma! @PlasmaCellPete looking as presidential as ever at the plenary session 💪 MonumenTAL-3: tal-dara +/- pom versus Dara-Pd. Tal-DP and tal-D both dramatically outperformed D-Pd! https://t.co/tp9t1XQyKK
#EHA2026 plenary session 👏 MonumenTAL-3: Tal-Dara and Tal-DaraPom both beat Dara-Pd in terms of PFS and OS. This is despite D-Pd doing the best it ever has (mPFS > 2 yrs). BsAbs, both BCMA and GPRC5D, are here to stay in earlier lines for myeloma! https://t.co/XsACbnIv7h
#EHA2026 MonumenTAL-3: Tal has real tongue/skin/cerebellar AEs, but what it doesn’t have is huge infection risk. Despite much longer time on Tx, fewer Gr3+ infections on tal-dara than Dara-Pd 🤯 GPRC5D doesn’t hit normal plasma cells, and #downwithdex in Tal-D(P) helps too! https://t.co/nvFyOf7Jvr
Rahul Banerjee, MD, FACP on EXCALIBER-RRMM
EXCALIBER-RRMM: IberDd mPFS 42 mo! I've said "harder, better, faster, stronger" for CELMoDs > IMiDs based on correlative data... now clinical data too 👏 mPFS 3.5 years on BCMA-free, IV-free, T-cell-sparing (likely T-strengthening) triplet in myeloma. Data coming at #ASH26! https://t.co/El2H6aeZOZ
#IMS26 @SagarLonialMD presenting EXCALIBER-RRMM. Finally, the Iber-Dd CELMoD data we've been eagerly awaiting! Rationale for presenting now, he just explained: Request from 🇺🇸 FDA not to release MRD-CR-based data before their formal approval. This is why I attend conferences! https://t.co/ub3NWs6xtH
3/ #IMS26 EXCALIBER-RRMM @SagarLonialMD et al And now paper out at @TheLancetOncol! https://t.co/DguduxLx82 https://t.co/EzbUGu7gXN
Rahul Banerjee, MD, FACP on MajesTEC-9
#EHA2026 and congrats #cyrilletouzeau and the whole MajesTEC-9 team for such excellent results! Tec monotherapy joins our growing landscape of excellent treatment options as early as first relapse 👏 https://t.co/Ui878e3tEi
MagnetisMM-5 press release - elra outperformed DPd in myeloma with 1+ prior line! Obviously all eyes will be on this vs MajesTEC-3 (and more pertinently, MajesTEC-9)… … but this confirms that the heyday of Dara-Pd and Isa-Pd at first relapse is rapidly coming to an end 👏 https://t.co/alzQ0578XK
🚨 Ph3 MajesTEC-9: Tec with PFS and OS ∆ in #MMsm. Last year*, I loudly tempered MajesTEC-3 by questioning tec-dara performance in CD38-refractory. [*Narrator's note: Last month] Now: I'll loudly say never mind: tec monoTx can hold the line! Congrats @RobertoMinaMD et al 👏 https://t.co/0Im1jCxVGI
Rahul Banerjee, MD, FACP on CERVINO
#IMS26 CERVINO plenary (pronounced 🪑 + 🇪🇸 🍷) by @PlasmaCellPete - Part 2. PPx toci is very clearly the way to go with any BsAb, and here it works quite well. Etentamig has low CD3 affinity like Velcro for T cells (credit @myelomatips ), which may explain part of this. https://t.co/cwkTM8opZO
#IMS26 CERVINO plenary (pronounced 🪑 + 🇪🇸 🍷) by @PlasmaCellPete Excellent results for BCMA BsAb therapy in early lines of R/R myeloma, this time with etentamig. It turns out we may be able to get to Q4W BsAb dosing as soon as C2D1! https://t.co/iUdr4jmZTn
Rahul Banerjee, MD, FACP on anito-cel
And with it, finally a new graphic to use for the different BCMA CAR-T therapies as opposed to the same one that all of you at #IMS26 can pick out from a mile away 👏 Congrats @MJFzeta et al on @NEJM paper and to @YiLinMDPhD for this very nice anito-cel editorial! https://t.co/isSV4RJL4D https://t.co/uPou1q22Cy
#IMS26 Just read through @NEJM anito-cel paper. 🐘 in room is of course vs cilta-cel / CARTITUDE-1. I'm always guilty of cross-trial comparisons, but here even I would advise against it... Relevant para(graphs) below. In world where we now bridge to ⬇️ myeloma, bridging success https://t.co/Z1pxl0auKX https://t.co/moACIjxj5e
Rahul Banerjee, MD, FACP on SUCCESSOR-2
This year, SUCCESSOR-2 showed half the risk of myeloma progression... using half the dose of a drug we commonly use. Let's dig into the evidence! cc @szusmani @khancology Watch the rest of the series from @mlieducation & get CE credit at https://t.co/rALTPoKlKB #RRMM #mmsm https://t.co/WUwyedT9MI
CELMoDs - that much closer to clinic 👏 SUCCESSOR-2 press release: Mezi-Kd beat Kd in registrational Ph3 trial. Data no doubt coming soon! I love KPd and will love this 100x more as pre-CAR holding/bridging or post-CAR/bsAb failure. T cells ❤️ mezi! https://t.co/umLNroSwxP https://t.co/TxSZ4RL1p1
Rahul Banerjee, MD, FACP on PERSEUS
#IMS26 #pietersonneveld presenting 6-yr (!) follow-up for PERSEUS. In standard-risk myeloma, 6-year PFS 88% 🤩 For HR cytogenetics, adding dara basically converts into standard-risk prognosis. Great, but we need to do better: BsAbs or CAR-T will be the way to close this gap. https://t.co/v2p7p3z1L8
Rahul Banerjee, MD, FACP’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Pleasure working with @ASCO on this! Living guidelines in myeloma #MMsm reflect how rapidly the field is changing... this update ≤6 months after our last one! CAR-T and bsAbs (tec-dara) now on equal footing for relapsed myeloma at first relapse - shared decision-making is 🔑 https://t.co/ZEHiMDeCH4 https://t.co/rczQDJDJAH
And I'll add, reviewing FDA announcement: ✅ Iberdomide approved in myeloma #MMsm after 1 prior line ✅ MRD-neg CR as basis for accel approval, woohoo! ✅ 41% MRD-neg CR with Iber-Dd in RRMM. Both DVd here and DKd in final CANDOR was ~20% MRD-neg CR, so essentially doubled. https://t.co/WNFtKCasFd
#IMS26 @Chhabra_mayo @myelomaMD et al For etentamig (BCMA BsAb) in BCMA-exposed myeloma (median 16 mo before), 58% ORR. More intriguingly - PPx toci way more useful than SUD to prevent CRS. Might SUD be replaced with toci in future to ⬇️ CRS and ⬇️⬇️ 🏥 LOS? I hope so! https://t.co/loWzACjoiU
#ASHKudos to @UrviShahMD for getting this to finish line in time for #ASH25! High fiber plant-based diets in myeloma precursors: Something our patients ask about, and something we have data for now! QOL, inflam benefits - and in some cases, alteration of #MMsm trajectory! https://t.co/wMuwDmyWR0
When it comes to BsAbs (and now trispecific) T-cell engagers in myeloma, less is often more once response is obtained! Excellent to see ramantimig holding the #IMS26 line with Q8W dosing, i.e. only ~6x 💉 per year. Probably lower IVIG needs at this dose frequency as well! https://t.co/hgyuifFewt https://t.co/N2gIqocSyb
Industry Payments
CMS Open Payments · 2025 general payments
$32,116 across 27 payments